The worst fear a cancer patient can experience is its relapse after long sessions of chemotherapeutic treatment. One of the main causes of failure in the treatment is the development of drug resistance by the cancer cells leading to recurrence of disease or even death. Such patients with resistant and responsive cancers have very limited therapeutic options available.
To find out the best way to tackle these grave complexities, three organizations collectively decided to spearhead their joint efforts in this direction. Manesar-based Sphaera Pharma along with LeadInvent Technologies, Delhi and International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi in July, 2011, initiated a project aimed at providing viable treatment option to the cancer patient population. The project received funding to the tune of Rs2 crore from Biotechnology Industry Partnership Program (BIPP) of the Department of Biotechnology (DBT), of which Sphaera Pharma received Rs1.48 crore, whereas LeadInvent accepted Rs35 lakh. ICGEB too, for their part received a certain amount of funding for their research efforts.
The R&D team at Sphaera is targeting important synergistic onco proteins, by taking the responsibility of studying the pharmacology in collaboration with their partner ICGEB, in identification of targets, medicinal chemistry and other profiling and evaluation assays.
Dr Kanury Rao and his team at ICGEB is looking at the pharmacological aspects of cell signaling, while the first series of molecules were designed by Sphaera and LeadInvent Technologies through LeadInvent's computational biology tools which helped in the understanding of the ligand-protein interactions. Sphaera has subsequently been able to design a series of compounds that are currently being evaluated and seem to be highly promising. The teams of respective organizations have been intracting constantly to share the progress and research insights.